First Time Loading...
M

Maccura Biotechnology Co Ltd
SZSE:300463

Watchlist Manager
Maccura Biotechnology Co Ltd
SZSE:300463
Watchlist
Price: 13.35 CNY -0.6%
Updated: May 15, 2024

Maccura Biotechnology Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maccura Biotechnology Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
603259
300759
2269
300347
1548

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
Maccura Biotechnology Co Ltd
SZSE:300463
Income from Continuing Operations
¥311.1m
CAGR 3-Years
-34%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income from Continuing Operations
¥9.7B
CAGR 3-Years
48%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income from Continuing Operations
¥1.4B
CAGR 3-Years
4%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income from Continuing Operations
¥3.6B
CAGR 3-Years
28%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income from Continuing Operations
¥1.9B
CAGR 3-Years
-9%
CAGR 5-Years
28%
CAGR 10-Years
34%
Genscript Biotech Corp
HKEX:1548
Income from Continuing Operations
-$355.1m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Maccura Biotechnology Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
311.1m CNY

Based on the financial report for Mar 31, 2024, Maccura Biotechnology Co Ltd's Income from Continuing Operations amounts to 311.1m CNY.

What is Maccura Biotechnology Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-9%

Over the last year, the Income from Continuing Operations growth was -49%. The average annual Income from Continuing Operations growth rates for Maccura Biotechnology Co Ltd have been -34% over the past three years , -9% over the past five years .